Milestones

Achievements to Date:
January 2004	Incorporation.
November 2005	TechnoVax was awarded $1.0 million in funding from The National Institutes of Health (NIH / U.S. Department of Health and Human Services ) to support development of its influenza vaccine program.
July 2006	Immunization with a TechnoVax H5N1 VLP vaccine provided 100% protection to mice challenged with a lethal dose of the highly pathogenic H5N1 influenza virus (bird flu).
December 2006	TechnoVax completed the licensing of the core VLP technology from Wyeth.
2006-2007	TechnoVax filed 4 additional patents on vaccines for a variety of viral diseases.
July 2007	TechnoVax developed and tested in mice and ferrets, two VLP vaccine candidates designed to provide protection against the 1918 (H1N1) influenza virus and the potentially pandemic H7N7 strain. Results were promising.
2007-2009	Development of bivalent VLP vaccine technology.
2008-2009	Development of RSV, HIV, cancer candidates (discovery stage).
September 2009	TechnoVax won $2.9 million in funding from The NIH (U.S. Department of Health and Human Services) to further support its vaccine programs.
October 2009	Initiated exploration for establishing potential regional partnerships worldwide.

Copyright © 2003-2009 TechnoVax. All rights reserved.   •   Website by AJ Network Solutions